GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Enzo Biochem Inc (NYSE:ENZ) » Definitions » Equity-to-Asset

Enzo Biochem (Enzo Biochem) Equity-to-Asset

: 0.71 (As of Jan. 2024)
View and export this data going back to 1980. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Enzo Biochem's Total Stockholders Equity for the quarter that ended in Jan. 2024 was $70.78 Mil. Enzo Biochem's Total Assets for the quarter that ended in Jan. 2024 was $99.08 Mil. Therefore, Enzo Biochem's Equity to Asset Ratio for the quarter that ended in Jan. 2024 was 0.71.

The historical rank and industry rank for Enzo Biochem's Equity-to-Asset or its related term are showing as below:

ENZ' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.26   Med: 0.63   Max: 0.83
Current: 0.71

During the past 13 years, the highest Equity to Asset Ratio of Enzo Biochem was 0.83. The lowest was 0.26. And the median was 0.63.

ENZ's Equity-to-Asset is ranked better than
64.02% of 239 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59 vs ENZ: 0.71

Enzo Biochem Equity-to-Asset Historical Data

The historical data trend for Enzo Biochem's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzo Biochem Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.81 0.52 0.60 0.72 0.64

Enzo Biochem Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 0.26 0.64 0.70 0.71

Competitive Comparison

For the Diagnostics & Research subindustry, Enzo Biochem's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzo Biochem Equity-to-Asset Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Enzo Biochem's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Enzo Biochem's Equity-to-Asset falls into.



Enzo Biochem Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Enzo Biochem's Equity to Asset Ratio for the fiscal year that ended in Jul. 2023 is calculated as

Equity to Asset (A: Jul. 2023 )=Total Stockholders Equity/Total Assets
=78.462/121.88
=0.64

Enzo Biochem's Equity to Asset Ratio for the quarter that ended in Jan. 2024 is calculated as

Equity to Asset (Q: Jan. 2024 )=Total Stockholders Equity/Total Assets
=70.775/99.077
=0.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enzo Biochem  (NYSE:ENZ) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Enzo Biochem Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Enzo Biochem's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzo Biochem (Enzo Biochem) Business Description

Traded in Other Exchanges
Address
527 Madison Avenue, New York, NY, USA, 10022
Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.
Executives
Steven J Pully director 9800 RICHMOND AVE, SUITE 700, HOUSTON TX 77042
James G. Wolf 10 percent owner 105, FLYWAY DRIVE, KIAWAH ISLAND SC 29455
Hamid Erfanian officer: Chief Executive Officer 527 MADISON AVENUE, NEW YORK NY 10022
Patricia Eckert officer: Interim CFO C/O ENZO BIOCHEM, INC., 81 EXECUTIVE BLVD, SUITE 3, FARMINGDALE NY 11735
Kara Cannon officer: Chief Operating Officer 527 MADISON AVE, NEW YORK NY 10022
Bradley Louis Radoff director 2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
David Bench officer: CHIEF FINANCIAL OFFICER ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Harbert Discovery Fund, Lp 10 percent owner HARBERT DISCOVERY FUND GP, LLC, 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Ian B. Walters director ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Mary Tagliaferri director 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Clemens Peter J Iv 10 percent owner 2383 N. BERRY'S CHAPEL RD., FRANKLIN TN 37069
Rebecca J. Fischer director ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Fabian Blank 10 percent owner, other: See Remarks ROEMERSTRASSE 6, BAD BERTRICH 2M 56864
Harbert Management Corp 10 percent owner 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Harbert Discovery Co-investment Fund I Gp, Llc 10 percent owner 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203